Regeneron Pharmaceuticals (REGN) Financials

$600.18 -14.61 (-2.38%)

As of 01:35 PM Eastern

Annual Income Statements for Regeneron Pharmaceuticals

This table shows Regeneron Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	4,413	3,954	4,338	8,075	3,513	2,116	2,444	1,199	896	636
Consolidated Net Income / (Loss)	4,413	3,954	4,338	8,075	3,513	2,116	2,444	1,199	896	636
Net Income / (Loss) Continuing Operations	4,413	3,954	4,338	8,075	3,513	2,116	2,444	1,199	896	636
Total Pre-Tax Income	4,780	4,199	4,859	9,326	3,810	2,429	2,554	2,079	1,330	1,225
Total Operating Income	3,991	4,047	4,739	8,947	3,577	2,210	2,534	2,080	1,331	1,252
Total Gross Profit	12,232	11,301	10,613	13,634	7,377	5,793	4,728	5,475	4,561	3,711
Total Revenue	14,202	13,117	12,173	16,072	8,497	6,558	5,146	5,872	4,860	4,104
Operating Revenue	14,202	13,117	12,173	16,072	8,497	6,558	5,146	5,872	4,860	4,029
Total Cost of Revenue	1,971	1,816	1,560	2,438	1,120	765	418	397	300	393
Operating Cost of Revenue	1,971	1,816	1,560	2,438	1,120	765	418	397	300	393
Total Operating Expenses	8,241	7,254	5,874	4,687	3,801	3,583	2,194	3,396	3,230	2,459
Selling, General & Admin Expense	2,954	2,631	2,116	1,825	1,346	1,342	1,127	1,320	1,178	839
Research & Development Expense	5,233	4,625	3,848	2,908	2,735	2,450	1,469	2,075	2,052	1,621
Other Operating Expenses / (Income)	53	-2.10	-90	-46	-280	-209	-402	-	-	-
Total Other Income / (Expense), net	789	152	120	379	234	219	19	-1.10	-1.80	-27
Interest Expense	55	73	59	57	57	30	28	25	7.20	-
Other Income / (Expense), net	844	225	179	436	291	250	47	24	5.40	-13
Income Tax Expense	367	246	520	1,251	297	313	109	880	434	589
Basic Earnings per Share	$40.90	$37.05	$40.51	$76.40	$32.65	$19.38	$22.65	$11.27	$8.55	$6.17
Weighted Average Basic Shares Outstanding	107.90M	106.70M	107.10M	105.70M	107.60M	109.20M	107.90M	106.30M	104.70M	103.06M
Diluted Earnings per Share	$38.34	$34.77	$38.22	$71.97	$30.52	$18.46	$21.29	$10.34	$7.70	$5.52
Weighted Average Diluted Shares Outstanding	115.10M	113.70M	113.50M	112.20M	115.10M	114.60M	114.80M	115.90M	116.30M	115.23M
Weighted Average Basic & Diluted Shares Outstanding	109.32M	109.76M	109.33M	108.54M	107.13M	110.02M	109.28M	106.30M	104.70M	103.10M

This table shows Regeneron Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	809	918	1,341	1,432	722	1,160	1,008	968	818	1,197	1,316
Consolidated Net Income / (Loss)	809	918	1,341	1,432	722	1,160	1,008	968	818	1,197	1,316
Net Income / (Loss) Continuing Operations	809	918	1,341	1,432	722	1,160	1,008	968	818	1,197	1,316
Total Pre-Tax Income	905	958	1,493	1,628	701	1,148	1,111	1,083	858	1,325	1,510
Total Operating Income	592	990	1,180	1,070	751	973	1,111	1,017	947	1,147	1,224
Total Gross Profit	2,564	3,224	3,230	3,067	2,711	2,917	2,926	2,753	2,705	2,874	2,618
Total Revenue	3,029	3,789	3,721	3,547	3,145	3,434	3,363	3,158	3,162	3,414	2,936
Operating Revenue	3,029	3,789	3,721	3,547	3,145	3,434	3,363	3,158	3,162	3,414	2,936
Total Cost of Revenue	464	565	491	480	434	517	436	405	458	541	318
Operating Cost of Revenue	464	565	491	480	434	517	436	405	458	541	318
Total Operating Expenses	1,973	2,234	2,050	1,997	1,960	1,944	1,815	1,737	1,758	1,727	1,395
Selling, General & Admin Expense	633	792	714	759	689	738	641	652	601	661	529
Research & Development Expense	1,340	1,426	1,328	1,224	1,256	1,207	1,175	1,085	1,157	1,073	911
Other Operating Expenses / (Income)	0.00	16	8.00	15	15	-0.50	-0.50	-0.60	-0.50	-6.60	-46
Total Other Income / (Expense), net	313	-32	314	559	-51	175	-0.20	66	-89	178	286
Interest Expense	8.70	11	14	15	16	18	18	19	18	17	15
Other Income / (Expense), net	322	-22	327	573	-35	193	18	85	-71	195	301
Income Tax Expense	96	40	152	196	-21	-12	103	115	40	128	194
Basic Earnings per Share	$7.58	$8.55	$12.40	$13.25	$6.70	$10.88	$9.48	$9.05	$7.64	$11.18	$12.31
Weighted Average Basic Shares Outstanding	106.70M	107.90M	108.10M	108.10M	107.80M	106.70M	106.30M	107M	107.10M	107.10M	106.90M
Diluted Earnings per Share	$7.27	$8.12	$11.54	$12.41	$6.27	$10.21	$8.89	$8.50	$7.17	$10.48	$11.66
Weighted Average Diluted Shares Outstanding	111.20M	115.10M	116.20M	115.40M	115.10M	113.70M	113.40M	113.90M	114M	113.50M	112.80M
Weighted Average Basic & Diluted Shares Outstanding	107.97M	109.32M	109.89M	110.23M	110.19M	109.76M	108.95M	108.56M	109.71M	109.33M	108.90M

This table details how cash moves in and out of Regeneron Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-249	-382	221	691	577	150	655	278	-261	160
Net Cash From Operating Activities	4,421	4,594	5,015	7,081	2,618	2,430	2,195	1,307	1,486	1,331
Net Cash From Continuing Operating Activities	4,421	4,594	5,015	7,081	2,618	2,430	2,195	1,307	1,486	1,331
Net Income / (Loss) Continuing Operations	4,413	3,954	4,338	8,075	3,513	2,116	2,444	1,199	896	636
Consolidated Net Income / (Loss)	4,413	3,954	4,338	8,075	3,513	2,116	2,444	1,199	896	636
Depreciation Expense	483	421	341	286	236	210	148	146	105	75
Non-Cash Adjustments To Reconcile Net Income	901	1,151	1,325	783	297	435	440	571	605	512
Changes in Operating Assets and Liabilities, net	-1,376	-932	-990	-2,064	-1,428	-331	-837	-608	-119	108
Net Cash From Investing Activities	-2,468	-3,185	-3,785	-5,385	-71	-2,028	-1,463	-1,005	-1,047	-908
Net Cash From Continuing Investing Activities	-2,468	-3,185	-3,785	-5,385	-71	-2,028	-1,463	-1,005	-1,047	-908
Purchase of Property, Plant & Equipment	-756	-719	-590	-552	-615	-430	-383	-273	-512	-678
Acquisitions	-17	-55	-230	0.00	0.00	-	-	-	-	-
Purchase of Investments	-16,617	-11,646	-7,488	-7,048	-3,241	-3,202	-1,846	-1,277	-809	-557
Sale of Property, Plant & Equipment	20	0.00	0.00	-	-	-	-	-	-	-
Sale and/or Maturity of Investments	15,027	9,442	5,551	2,215	3,785	1,604	776	545	275	327
Other Investing Activities, net	-126	-208	-1,027	0.00	0.00	-	-10	0.00	0.00	-
Net Cash From Financing Activities	-2,201	-1,790	-1,009	-1,006	-1,971	-252	-77	-24	-701	-263
Net Cash From Continuing Financing Activities	-2,201	-1,790	-1,009	-1,006	-1,971	-252	-77	-24	-701	-263
Repayment of Debt	-33	0.00	0.00	-	-1,500	0.00	0.00	-20	-46	-168
Repurchase of Common Equity	-2,603	-2,235	-2,083	-1,645	-5,847	-276	-4.40	0.00	-643	-573
Issuance of Common Equity	1,465	1,146	1,520	1,672	2,575	212	115	240	127	206
Other Financing Activities, net	-1,029	-701	-446	-1,033	-681	-188	-187	-302	-143	245
Effect of Exchange Rate Changes	-0.70	-0.40	0.00	0.00	-	-	-	-	-	-
Cash Interest Paid	53	73	54	56	23	25	22	19	5.50	11
Cash Income Taxes Paid	743	870	1,502	1,218	188	342	206	755	481	276

This table details how cash moves in and out of Regeneron Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	604	477	84	-682	-128	578	211	-1,979	809	-385	96
Net Cash From Operating Activities	1,045	1,263	1,291	354	1,513	1,090	1,114	1,022	1,368	1,720	629
Net Cash From Continuing Operating Activities	1,045	1,263	1,291	354	1,513	1,090	1,114	1,022	1,368	1,720	629
Net Income / (Loss) Continuing Operations	809	918	1,341	1,432	722	1,160	1,008	968	818	1,197	1,316
Consolidated Net Income / (Loss)	809	918	1,341	1,432	722	1,160	1,008	968	818	1,197	1,316
Depreciation Expense	127	126	122	121	114	113	105	103	100	100	93
Non-Cash Adjustments To Reconcile Net Income	119	585	61	-172	426	165	319	242	426	320	-27
Changes in Operating Assets and Liabilities, net	-9.50	-367	-233	-1,027	250	-348	-318	-291	24	102	-753
Net Cash From Investing Activities	648	351	-574	-557	-1,687	-66	-496	-2,387	-236	-1,858	192
Net Cash From Continuing Investing Activities	648	351	-574	-557	-1,687	-66	-496	-2,387	-236	-1,858	192
Purchase of Property, Plant & Equipment	-229	-200	-242	-181	-134	-251	-176	-113	-178	-152	-143
Purchase of Investments	-2,539	-1,953	-4,591	-4,416	-5,658	-2,132	-3,243	-4,522	-1,749	-3,143	-570
Sale and/or Maturity of Investments	3,458	2,582	4,259	4,055	4,132	2,383	2,998	2,269	1,793	1,537	1,832
Other Investing Activities, net	-42	-67	-	-30	-28	-62	-24	-21	-101	-100	-927
Net Cash From Financing Activities	-1,089	-1,136	-634	-478	47	-446	-407	-614	-323	-248	-725
Net Cash From Continuing Financing Activities	-1,089	-1,136	-634	-478	47	-446	-407	-614	-323	-248	-725
Repayment of Debt	-10	-	-	-	-	-	-	-	-	-	-
Repurchase of Common Equity	-1,041	-973	-735	-604	-291	-289	-547	-689	-711	-431	-935
Payment of Dividends	-94	-	-	-	-	-	-	-	-	-	-
Issuance of Common Equity	61	91	255	438	682	301	269	91	485	373	319
Other Financing Activities, net	-4.30	-253	-120	-312	-344	-458	-129	-16	-97	-189	-109
Effect of Exchange Rate Changes	0.60	-0.70	0.80	-0.30	-0.50	0.20	-0.20	-0.40	0.00	-	-

This table presents Regeneron Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	37,759	33,080	29,215	25,435	17,163	14,805	11,735	8,764	6,973	5,609
Total Current Assets	18,661	19,479	15,884	14,015	9,779	7,689	6,448	4,335	3,180	2,915
Cash & Equivalents	2,488	2,730	3,106	2,886	2,194	1,618	1,468	813	535	809
Short-Term Investments	6,524	8,115	4,636	2,809	1,393	1,597	1,342	597	503	236
Accounts Receivable	6,212	5,667	5,329	6,037	4,115	2,786	2,243	1,974	1,612	1,468
Inventories, net	3,087	2,581	2,402	1,951	1,917	1,416	1,151	726	399	239
Prepaid Expenses	349	387	411	332	161	274	243	225	131	164
Plant, Property, & Equipment, net	4,600	4,146	3,763	3,482	0.00	0.00	2,576	2,359	2,083	1,594
Total Noncurrent Assets	14,499	9,455	9,567	7,938	7,384	7,116	2,711	2,071	1,710	1,100
Long-Term Investments	8,900	5,397	6,592	6,838	3,136	3,257	1,755	1,487	864	632
Intangible Assets	1,149	1,039	916	6.70	-	-	-	-	-	-
Noncurrent Deferred & Refundable Income Taxes	3,314	2,575	1,724	877	859	824	829	506	825	462
Other Noncurrent Operating Assets	1,136	444	336	216	3,390	3,035	127	78	20	5.81
Total Liabilities & Shareholders' Equity	37,759	33,080	29,215	25,435	17,163	14,805	11,735	8,764	6,973	5,609
Total Liabilities	8,406	7,107	6,551	6,666	6,138	3,716	2,977	2,620	2,524	1,954
Total Current Liabilities	3,944	3,423	3,141	3,933	2,697	2,097	1,443	1,136	1,241	811
Accounts Payable	790	607	589	564	476	418	218	178	879	644
Accrued Expenses	2,527	2,358	2,074	2,207	1,644	1,211	772	637	-	-
Current Deferred Revenue	628	459	478	442	578	382	453	320	232	153
Total Noncurrent Liabilities	4,462	3,684	3,409	2,734	3,441	1,619	1,534	1,485	1,283	1,143
Long-Term Debt	1,984	1,983	1,981	1,980	1,979	0.00	-	-	-	-
Capital Lease Obligations	720	720	720	-	717	714	709	704	352	363
Noncurrent Deferred Revenue	186	127	70	73	58	105	464	629	831	665
Other Noncurrent Operating Liabilities	1,571	854	638	680	687	800	362	152	100	116
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	29,354	25,973	22,664	18,769	11,025	11,090	8,757	6,144	4,449	3,655
Total Preferred & Common Equity	29,354	25,973	22,664	18,769	11,025	11,090	8,757	6,144	4,449	3,655
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	29,354	25,973	22,664	18,769	11,025	11,090	8,757	6,144	4,449	3,655
Common Stock	12,856	11,354	9,949	8,088	6,716	4,429	3,912	3,513	3,030	3,100
Retained Earnings	31,673	27,260	23,307	18,968	10,893	7,380	5,254	2,947	1,748	853
Treasury Stock	-15,167	-12,560	-10,353	-8,261	-6,613	-740	-396	-316	-316	-306
Accumulated Other Comprehensive Income / (Loss)	-7.90	-81	-239	-26	29	21	-12	0.60	-13	8.57

This table presents Regeneron Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	37,545	37,759	37,442	36,087	34,370	33,080	32,163	30,658	30,060	29,215	27,678
Total Current Assets	17,572	18,661	19,334	19,082	18,872	19,479	18,635	16,923	16,909	15,884	15,429
Cash & Equivalents	3,090	2,488	2,012	1,921	2,602	2,730	2,152	1,937	3,916	3,106	3,491
Short-Term Investments	5,259	6,524	7,785	7,888	7,918	8,115	7,761	6,991	5,043	4,636	3,530
Accounts Receivable	5,561	6,212	6,107	5,717	5,222	5,667	5,585	5,121	5,119	5,329	5,548
Inventories, net	3,192	3,087	3,018	2,874	2,715	2,581	2,562	2,508	2,425	2,402	2,412
Prepaid Expenses	469	349	412	682	415	387	575	366	406	411	446
Plant, Property, & Equipment, net	4,694	4,600	4,439	4,306	4,226	4,146	4,006	3,923	3,881	3,763	3,704
Total Noncurrent Assets	15,279	14,499	13,669	12,699	11,273	9,455	9,522	9,812	9,270	9,567	8,545
Long-Term Investments	9,276	8,900	8,491	7,722	6,979	5,397	5,779	6,327	6,067	6,592	5,969
Intangible Assets	1,167	1,149	1,120	1,102	1,059	1,039	1,017	953	929	916	804
Noncurrent Deferred & Refundable Income Taxes	3,443	3,314	3,015	2,881	2,765	2,575	2,317	2,139	1,925	1,724	1,452
Other Noncurrent Operating Assets	1,393	1,136	1,043	994	470	444	410	393	350	336	320
Total Liabilities & Shareholders' Equity	37,545	37,759	37,442	36,087	34,370	33,080	32,163	30,658	30,060	29,215	27,678
Total Liabilities	8,158	8,406	8,116	7,881	7,379	7,107	7,259	6,640	6,565	6,551	6,239
Total Current Liabilities	3,567	3,944	3,661	3,509	3,581	3,423	3,599	3,104	3,100	3,141	2,879
Accounts Payable	706	790	497	562	671	607	537	547	600	589	536
Accrued Expenses	2,242	2,527	2,537	2,361	2,393	2,358	2,645	2,176	2,074	2,074	1,796
Current Deferred Revenue	619	628	627	586	517	459	417	381	426	478	547
Total Noncurrent Liabilities	4,591	4,462	4,455	4,372	3,798	3,684	3,660	3,535	3,465	3,409	3,360
Long-Term Debt	1,985	1,984	1,984	1,984	1,983	1,983	1,983	1,982	1,982	1,981	1,981
Capital Lease Obligations	720	720	720	720	720	720	720	720	720	720	720
Noncurrent Deferred Revenue	212	186	207	206	186	127	125	116	86	70	60
Other Noncurrent Operating Liabilities	1,674	1,571	1,544	1,463	909	854	832	717	677	638	599
Total Equity & Noncontrolling Interests	29,388	29,354	29,326	28,206	26,991	25,973	24,904	24,018	23,495	22,664	21,439
Total Preferred & Common Equity	29,388	29,354	29,326	28,206	26,991	25,973	24,904	24,018	23,495	22,664	21,439
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	29,388	29,354	29,326	28,206	26,991	25,973	24,904	24,018	23,495	22,664	21,439
Common Stock	13,192	12,856	12,703	12,317	11,943	11,354	11,252	10,889	10,598	9,949	9,518
Retained Earnings	32,384	31,673	30,755	29,415	27,982	27,260	26,101	25,093	24,125	23,307	22,110
Treasury Stock	-16,218	-15,167	-14,192	-13,456	-12,857	-12,560	-12,271	-11,766	-11,046	-10,353	-9,914
Accumulated Other Comprehensive Income / (Loss)	29	-7.90	60	-70	-77	-81	-177	-198	-182	-239	-275

This table displays calculated financial ratios and metrics derived from Regeneron Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.27%	7.76%	-24.26%	89.14%	29.58%	27.44%	-12.37%	20.82%	18.44%	45.55%
EBITDA Growth	13.31%	-10.77%	-45.61%	135.65%	53.70%	-2.21%	21.38%	56.10%	9.63%	54.38%
EBIT Growth	13.17%	-13.13%	-47.58%	142.63%	57.25%	-4.74%	22.73%	57.44%	7.81%	55.19%
NOPAT Growth	-3.31%	-9.95%	-45.38%	134.93%	71.32%	-20.66%	102.32%	33.82%	37.87%	77.61%
Net Income Growth	11.61%	-8.87%	-46.28%	129.86%	66.05%	-13.44%	103.95%	33.84%	40.79%	88.11%
EPS Growth	10.27%	-9.03%	-46.89%	135.81%	65.33%	-13.29%	105.90%	34.29%	39.49%	85.23%
Operating Cash Flow Growth	-3.78%	-8.39%	-29.18%	170.47%	7.74%	10.70%	67.94%	-12.03%	11.66%	76.86%
Free Cash Flow Firm Growth	-18.01%	69.96%	-78.31%	300.15%	9.28%	1.11%	437.10%	31.53%	585.45%	-147.11%
Invested Capital Growth	13.76%	12.72%	34.26%	17.40%	31.24%	8.81%	24.02%	30.53%	29.36%	42.07%
Revenue Q/Q Growth	2.56%	0.15%	-11.21%	18.67%	7.05%	29.68%	-19.16%	6.45%	2.72%	7.77%
EBITDA Q/Q Growth	-3.34%	-3.36%	-17.94%	15.41%	9.33%	9.18%	5.04%	11.01%	7.77%	5.54%
EBIT Q/Q Growth	-3.92%	-3.96%	-19.29%	15.77%	9.73%	9.48%	5.00%	11.52%	7.91%	5.11%
NOPAT Q/Q Growth	-1.01%	-1.02%	-23.67%	19.23%	17.71%	-11.70%	39.38%	-7.29%	12.45%	9.28%
Net Income Q/Q Growth	-5.20%	-0.94%	-19.21%	15.44%	11.32%	-1.32%	35.98%	-6.23%	12.30%	11.36%
EPS Q/Q Growth	-5.17%	-0.77%	-19.23%	15.19%	11.55%	-1.12%	35.86%	-5.74%	11.59%	11.29%
Operating Cash Flow Q/Q Growth	4.08%	-12.06%	-11.51%	19.22%	20.40%	2.47%	7.96%	15.62%	7.88%	6.71%
Free Cash Flow Firm Q/Q Growth	4.19%	-21.96%	-35.99%	33.76%	-10.61%	2.07%	15.51%	161.21%	-65.54%	-142.44%
Invested Capital Q/Q Growth	2.93%	4.36%	-1.06%	5.08%	12.83%	2.03%	8.67%	-2.37%	31.34%	10.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	86.13%	86.16%	87.18%	84.83%	86.82%	88.33%	91.89%	93.24%	93.83%	90.43%
EBITDA Margin	37.45%	35.78%	43.21%	60.16%	48.29%	40.71%	53.05%	38.30%	29.64%	32.03%
Operating Margin	28.10%	30.85%	38.93%	55.67%	42.09%	33.70%	49.25%	35.41%	27.38%	30.51%
EBIT Margin	34.05%	32.57%	40.40%	58.38%	45.51%	37.50%	50.17%	35.82%	27.49%	30.20%
Profit (Net Income) Margin	31.07%	30.14%	35.64%	50.25%	41.35%	32.26%	47.50%	20.41%	18.42%	15.50%
Tax Burden Percent	92.32%	94.15%	89.29%	86.59%	92.20%	87.10%	95.73%	57.66%	67.34%	51.92%
Interest Burden Percent	98.86%	98.29%	98.79%	99.39%	98.53%	98.77%	98.91%	98.81%	99.53%	98.85%
Effective Tax Rate	7.68%	5.85%	10.71%	13.41%	7.80%	12.90%	4.27%	42.34%	32.66%	48.08%
Return on Invested Capital (ROIC)	27.72%	32.48%	43.97%	101.84%	53.49%	37.62%	54.81%	34.36%	33.39%	32.60%
ROIC Less NNEP Spread (ROIC-NNEP)	22.65%	31.34%	43.00%	97.34%	49.08%	33.64%	54.21%	34.40%	33.43%	33.86%
Return on Net Nonoperating Assets (RNNOA)	-11.77%	-16.22%	-23.03%	-47.63%	-21.71%	-16.30%	-22.00%	-11.74%	-11.29%	-12.10%
Return on Equity (ROE)	15.95%	16.26%	20.94%	54.21%	31.77%	21.32%	32.81%	22.63%	22.10%	20.50%
Cash Return on Invested Capital (CROIC)	14.85%	20.51%	14.72%	85.83%	26.47%	29.18%	33.36%	7.88%	7.79%	-2.16%
Operating Return on Assets (OROA)	13.65%	13.72%	18.00%	44.05%	24.19%	18.53%	25.19%	26.73%	21.24%	26.24%
Return on Assets (ROA)	12.46%	12.69%	15.88%	37.91%	21.98%	15.94%	23.85%	15.23%	14.23%	13.47%
Return on Common Equity (ROCE)	15.95%	16.26%	20.94%	54.21%	31.77%	21.32%	32.81%	22.63%	22.10%	20.50%
Return on Equity Simple (ROE_SIMPLE)	15.03%	15.22%	19.14%	43.03%	31.86%	19.08%	27.91%	19.51%	20.13%	17.40%
Net Operating Profit after Tax (NOPAT)	3,684	3,810	4,231	7,747	3,298	1,925	2,426	1,199	896	650
NOPAT Margin	25.94%	29.05%	34.76%	48.20%	38.81%	29.35%	47.15%	20.42%	18.44%	15.84%
Net Nonoperating Expense Percent (NNEP)	5.07%	1.14%	0.97%	4.50%	4.41%	3.97%	0.60%	-0.04%	-0.04%	-1.26%
Return On Investment Capital (ROIC_SIMPLE)	11.49%	13.29%	16.68%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	13.87%	13.84%	12.82%	15.17%	13.18%	11.67%	8.11%	6.76%	6.17%	9.57%
SG&A Expenses to Revenue	20.80%	20.06%	17.38%	11.35%	15.84%	20.46%	21.91%	22.49%	24.23%	20.43%
R&D to Revenue	36.85%	35.26%	31.61%	18.09%	32.19%	37.36%	28.54%	35.34%	42.22%	39.49%
Operating Expenses to Revenue	58.03%	55.30%	48.25%	29.17%	44.73%	54.63%	42.63%	57.82%	66.46%	59.92%
Earnings before Interest and Taxes (EBIT)	4,835	4,272	4,918	9,383	3,867	2,459	2,582	2,104	1,336	1,239
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	5,318	4,693	5,260	9,669	4,103	2,670	2,730	2,249	1,441	1,314
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.67	3.68	3.47	3.62	4.68	3.72	4.62	6.57	8.70	15.46
Price to Tangible Book Value (P/TBV)	2.78	3.84	3.61	3.62	4.68	3.72	4.62	6.57	8.70	15.46
Price to Revenue (P/Rev)	5.51	7.29	6.45	4.23	6.07	6.29	7.86	6.88	7.97	13.77
Price to Earnings (P/E)	17.74	24.20	18.11	8.41	14.67	19.48	16.54	33.70	43.24	88.82
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	5.64%	4.13%	5.52%	11.89%	6.82%	5.13%	6.05%	2.97%	2.31%	1.13%
Enterprise Value to Invested Capital (EV/IC)	4.46	6.61	6.07	6.98	6.79	6.65	7.46	9.67	12.32	23.58
Enterprise Value to Revenue (EV/Rev)	4.44	6.26	5.50	3.57	5.59	5.41	7.11	6.51	7.67	13.45
Enterprise Value to EBITDA (EV/EBITDA)	11.86	17.50	12.73	5.93	11.58	13.29	13.40	16.98	25.89	41.99
Enterprise Value to EBIT (EV/EBIT)	13.04	19.23	13.61	6.11	12.29	14.42	14.16	18.16	27.91	44.52
Enterprise Value to NOPAT (EV/NOPAT)	17.12	21.56	15.82	7.40	14.41	18.43	15.07	31.86	41.62	84.89
Enterprise Value to Operating Cash Flow (EV/OCF)	14.27	17.88	13.35	8.10	18.15	14.60	16.66	29.23	25.10	41.46
Enterprise Value to Free Cash Flow (EV/FCFF)	31.96	34.13	47.27	8.79	29.12	23.75	24.76	138.93	178.40	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.09	0.10	0.12	0.11	0.24	0.06	0.08	0.11	0.11	0.10
Long-Term Debt to Equity	0.09	0.10	0.12	0.11	0.24	0.06	0.08	0.11	0.08	0.10
Financial Leverage	-0.52	-0.52	-0.54	-0.49	-0.44	-0.48	-0.41	-0.34	-0.34	-0.36
Leverage Ratio	1.28	1.28	1.32	1.43	1.45	1.34	1.38	1.49	1.55	1.52
Compound Leverage Factor	1.27	1.26	1.30	1.42	1.42	1.32	1.36	1.47	1.55	1.50
Debt to Total Capital	8.44%	9.43%	10.65%	9.54%	19.65%	6.05%	7.48%	10.27%	9.76%	9.03%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.63%	0.00%
Long-Term Debt to Total Capital	8.44%	9.43%	10.65%	9.54%	19.65%	6.05%	7.48%	10.27%	7.13%	9.03%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.56%	90.57%	89.35%	90.46%	80.35%	93.95%	92.51%	89.73%	90.24%	90.97%
Debt to EBITDA	0.51	0.58	0.51	0.20	0.66	0.27	0.26	0.31	0.33	0.28
Net Debt to EBITDA	-2.86	-2.88	-2.21	-1.09	-0.98	-2.16	-1.41	-0.97	-0.99	-1.00
Long-Term Debt to EBITDA	0.51	0.58	0.51	0.20	0.66	0.27	0.26	0.31	0.24	0.28
Debt to NOPAT	0.73	0.71	0.64	0.26	0.82	0.37	0.29	0.59	0.54	0.56
Net Debt to NOPAT	-4.13	-3.55	-2.75	-1.36	-1.22	-2.99	-1.59	-1.83	-1.59	-2.02
Long-Term Debt to NOPAT	0.73	0.71	0.64	0.26	0.82	0.37	0.29	0.59	0.39	0.56
Altman Z-Score	8.03	10.64	9.81	9.48	7.66	8.80	10.45	11.62	11.22	19.47
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.73	5.69	5.06	3.56	3.63	3.67	4.47	3.82	2.56	3.59
Quick Ratio	3.86	4.82	4.16	2.98	2.86	2.86	3.50	2.98	2.13	3.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,973	2,407	1,416	6,529	1,632	1,493	1,477	275	209	-43
Operating Cash Flow to CapEx	600.77%	639.30%	849.84%	1,283.08%	425.98%	565.64%	572.98%	479.49%	290.27%	196.30%
Free Cash Flow to Firm to Interest Expense	35.75	32.97	23.84	113.95	28.68	49.44	52.37	10.95	29.03	0.00
Operating Cash Flow to Interest Expense	80.08	62.93	84.43	123.58	46.01	80.46	77.84	52.08	206.38	0.00
Operating Cash Flow Less CapEx to Interest Expense	66.75	53.09	74.49	113.95	35.21	66.24	64.26	41.22	135.28	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.40	0.42	0.45	0.75	0.53	0.49	0.50	0.75	0.77	0.87
Accounts Receivable Turnover	2.39	2.39	2.14	3.17	2.46	2.61	2.44	3.28	3.16	3.36
Inventory Turnover	0.70	0.73	0.72	1.26	0.67	0.60	0.44	0.71	0.94	2.14
Fixed Asset Turnover	3.25	3.32	3.36	0.00	0.00	0.00	2.09	2.64	2.64	3.20
Accounts Payable Turnover	2.82	3.04	2.71	4.69	2.51	2.40	2.11	0.75	0.39	0.70
Days Sales Outstanding (DSO)	152.65	152.99	170.39	115.27	148.20	139.95	149.58	111.45	115.63	108.70
Days Inventory Outstanding (DIO)	524.93	500.76	509.14	289.60	543.00	612.24	820.62	517.24	388.47	170.76
Days Payable Outstanding (DPO)	129.30	120.19	134.88	77.83	145.62	151.78	173.28	485.91	927.55	524.02
Cash Conversion Cycle (CCC)	548.28	533.57	544.65	327.04	545.58	600.41	796.92	142.77	-423.45	-244.57
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	14,145	12,435	11,031	8,216	6,998	5,333	4,901	3,952	3,027	2,340
Invested Capital Turnover	1.07	1.12	1.26	2.11	1.38	1.28	1.16	1.68	1.81	2.06
Increase / (Decrease) in Invested Capital	1,711	1,403	2,815	1,218	1,666	432	949	924	687	693
Enterprise Value (EV)	63,069	82,149	66,939	57,363	47,524	35,469	36,569	38,200	37,295	55,179
Market Capitalization	78,278	95,687	78,572	67,916	51,551	41,226	40,426	40,393	38,717	56,494
Book Value per Share	$267.12	$238.40	$208.11	$174.52	$103.32	$101.00	$80.91	$57.19	$42.18	$35.12
Tangible Book Value per Share	$256.67	$228.87	$199.71	$174.46	$103.32	$101.00	$80.91	$57.19	$42.18	$35.12
Total Capital	32,058	28,676	25,366	20,749	13,721	11,804	9,466	6,848	4,930	4,018
Total Debt	2,704	2,703	2,701	1,980	2,696	714	709	704	481	363
Total Long-Term Debt	2,704	2,703	2,701	1,980	2,696	714	709	704	352	363
Net Debt	-15,208	-13,538	-11,633	-10,553	-4,027	-5,757	-3,856	-2,193	-1,422	-1,314
Capital Expenditures (CapEx)	736	719	590	552	615	430	383	273	512	678
Debt-free, Cash-free Net Working Capital (DFCFNWC)	5,704	5,211	5,001	4,388	3,495	2,378	2,195	1,790	1,030	1,059
Debt-free Net Working Capital (DFNWC)	14,717	16,056	12,743	10,082	7,082	5,593	5,005	3,200	2,068	2,104
Net Working Capital (NWC)	14,717	16,056	12,743	10,082	7,082	5,593	5,005	3,200	1,939	2,104
Net Nonoperating Expense (NNE)	-729	-143	-107	-328	-216	-191	-18	0.63	0.61	14
Net Nonoperating Obligations (NNO)	-15,208	-13,538	-11,633	-10,553	-4,027	-5,757	-3,856	-2,193	-1,422	-1,314
Total Depreciation and Amortization (D&A)	483	421	341	286	236	210	148	146	105	75
Debt-free, Cash-free Net Working Capital to Revenue	40.16%	39.73%	41.08%	27.30%	41.13%	36.27%	42.66%	30.48%	21.18%	25.80%
Debt-free Net Working Capital to Revenue	103.62%	122.40%	104.68%	62.73%	83.34%	85.28%	97.26%	54.49%	42.55%	51.27%
Net Working Capital to Revenue	103.62%	122.40%	104.68%	62.73%	83.34%	85.28%	97.26%	54.49%	39.89%	51.27%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$40.90	$37.05	$40.51	$76.40	$32.65	$19.38	$22.65	$11.27	$8.55	$6.17
Adjusted Weighted Average Basic Shares Outstanding	107.90M	106.70M	107.10M	105.70M	107.60M	109.20M	107.90M	106.34M	104.72M	103.06M
Adjusted Diluted Earnings per Share	$38.34	$34.77	$38.22	$71.97	$30.52	$18.46	$21.29	$10.34	$7.70	$5.52
Adjusted Weighted Average Diluted Shares Outstanding	115.10M	113.70M	113.50M	112.20M	115.10M	114.60M	114.80M	115.95M	116.37M	115.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$19.38	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	109.32M	109.76M	109.33M	108.54M	107.13M	110.02M	109.28M	107.70M	106.08M	104.79M
Normalized Net Operating Profit after Tax (NOPAT)	3,684	3,810	4,231	7,747	3,298	1,925	2,426	1,199	896	650
Normalized NOPAT Margin	25.94%	29.05%	34.76%	48.20%	38.81%	29.35%	47.15%	20.42%	18.44%	15.84%
Pre Tax Income Margin	33.66%	32.01%	39.91%	58.03%	44.84%	37.04%	49.62%	35.40%	27.36%	29.85%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	87.59	58.52	82.80	163.75	67.97	81.43	91.55	83.81	185.57	0.00
NOPAT to Interest Expense	66.74	52.20	71.23	135.20	57.95	63.73	86.03	47.77	124.46	0.00
EBIT Less CapEx to Interest Expense	74.26	48.68	72.86	154.12	57.17	67.21	77.96	72.95	114.47	0.00
NOPAT Less CapEx to Interest Expense	53.41	42.35	61.30	125.57	47.15	49.51	72.45	36.91	53.36	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	59.00%	56.53%	48.01%	20.38%	166.42%	13.04%	0.18%	0.00%	71.85%	90.16%

This table displays calculated financial ratios and metrics derived from Regeneron Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.70%	10.33%	10.65%	12.32%	-0.54%	0.58%	14.53%	10.53%	6.64%	-31.05%	-14.96%
EBITDA Growth	25.24%	-14.38%	31.97%	46.37%	-14.82%	-11.32%	-23.72%	14.68%	-15.10%	-44.36%	-15.04%
EBIT Growth	27.47%	-16.92%	33.51%	49.11%	-18.17%	-13.13%	-26.00%	12.85%	-18.49%	-46.69%	-16.70%
NOPAT Growth	-31.71%	-3.52%	5.07%	3.51%	-14.20%	-5.14%	-5.48%	-7.42%	-21.85%	-55.91%	-35.75%
Net Income Growth	12.01%	-20.86%	33.02%	47.90%	-11.71%	-3.13%	-23.40%	13.65%	-15.99%	-46.29%	-19.39%
EPS Growth	15.95%	-20.47%	29.81%	46.00%	-12.55%	-2.58%	-23.76%	13.79%	-16.72%	-46.48%	-18.63%
Operating Cash Flow Growth	-30.90%	15.89%	15.88%	-65.38%	10.60%	-36.64%	77.18%	81.15%	-34.93%	-27.51%	-81.58%
Free Cash Flow Firm Growth	-593.53%	-81.35%	-416.67%	15.49%	85.95%	76.37%	110.72%	-232.02%	-328.23%	-257.05%	-5,270.86%
Invested Capital Growth	18.62%	13.76%	15.34%	16.68%	9.18%	12.72%	6.86%	21.89%	31.72%	34.26%	42.60%
Revenue Q/Q Growth	-20.07%	1.84%	4.89%	12.79%	-8.42%	2.13%	6.48%	-0.13%	-7.39%	16.29%	2.76%
EBITDA Q/Q Growth	-4.97%	-32.76%	-7.66%	112.25%	-35.03%	3.64%	2.42%	23.52%	-32.36%	-10.85%	53.96%
EBIT Q/Q Growth	-5.67%	-35.72%	-8.28%	129.20%	-38.52%	3.31%	2.43%	25.78%	-34.73%	-12.00%	56.21%
NOPAT Q/Q Growth	-44.25%	-10.45%	12.55%	21.53%	-21.24%	-2.47%	10.89%	0.74%	-12.93%	-2.82%	8.61%
Net Income Q/Q Growth	-11.88%	-31.55%	-6.40%	98.38%	-37.74%	15.06%	4.07%	18.42%	-31.68%	-9.01%	54.41%
EPS Q/Q Growth	-10.47%	-29.64%	-7.01%	97.93%	-38.59%	14.85%	4.59%	18.55%	-31.58%	-10.12%	56.09%
Operating Cash Flow Q/Q Growth	-17.24%	-2.20%	264.75%	-76.60%	38.80%	-2.21%	8.99%	-25.24%	-20.48%	173.48%	11.43%
Free Cash Flow Firm Q/Q Growth	-128.51%	0.81%	20.92%	-286.94%	40.25%	-273.20%	121.10%	35.68%	-0.51%	21.45%	-359.97%
Invested Capital Q/Q Growth	2.27%	2.93%	2.72%	9.69%	-1.92%	4.36%	3.92%	2.64%	1.26%	-1.06%	18.53%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	84.67%	85.08%	86.80%	86.46%	86.21%	84.95%	87.02%	87.18%	85.53%	84.17%	89.18%
EBITDA Margin	34.36%	28.90%	43.77%	49.72%	26.42%	37.24%	36.70%	38.15%	30.85%	42.24%	55.10%
Operating Margin	19.54%	26.13%	31.70%	30.15%	23.89%	28.33%	33.04%	32.19%	29.94%	33.59%	41.68%
EBIT Margin	30.17%	25.56%	40.50%	46.32%	22.79%	33.95%	33.56%	34.89%	27.70%	39.31%	51.94%
Profit (Net Income) Margin	26.70%	24.22%	36.03%	40.38%	22.96%	33.77%	29.97%	30.66%	25.86%	35.06%	44.81%
Tax Burden Percent	89.36%	95.78%	89.79%	87.97%	103.04%	101.05%	90.73%	89.43%	95.31%	90.37%	87.14%
Interest Burden Percent	99.05%	98.92%	99.08%	99.10%	97.75%	98.43%	98.42%	98.28%	97.95%	98.70%	99.00%
Effective Tax Rate	10.64%	4.22%	10.21%	12.03%	-3.04%	-1.05%	9.27%	10.57%	4.69%	9.63%	12.86%
Return on Invested Capital (ROIC)	18.45%	26.75%	30.72%	28.81%	27.60%	32.00%	34.04%	34.95%	35.93%	38.39%	52.50%
ROIC Less NNEP Spread (ROIC-NNEP)	16.56%	26.96%	28.75%	25.22%	27.99%	30.60%	34.04%	34.45%	36.64%	36.94%	49.97%
Return on Net Nonoperating Assets (RNNOA)	-8.73%	-14.01%	-15.15%	-13.22%	-15.03%	-15.84%	-17.10%	-18.37%	-20.05%	-19.78%	-25.48%
Return on Equity (ROE)	9.72%	12.74%	15.57%	15.59%	12.57%	16.17%	16.94%	16.58%	15.87%	18.61%	27.02%
Cash Return on Invested Capital (CROIC)	8.91%	14.85%	14.76%	14.22%	22.69%	20.51%	26.74%	17.65%	13.10%	14.72%	23.33%
Operating Return on Assets (OROA)	11.82%	10.25%	16.11%	18.72%	9.27%	14.30%	14.69%	15.28%	12.15%	17.51%	27.74%
Return on Assets (ROA)	10.46%	9.71%	14.34%	16.32%	9.34%	14.22%	13.12%	13.43%	11.34%	15.62%	23.93%
Return on Common Equity (ROCE)	9.72%	12.74%	15.57%	15.59%	12.57%	16.17%	16.94%	16.58%	15.87%	18.61%	27.02%
Return on Equity Simple (ROE_SIMPLE)	15.31%	0.00%	15.87%	15.32%	14.29%	0.00%	16.03%	17.90%	17.80%	0.00%	25.05%
Net Operating Profit after Tax (NOPAT)	529	948	1,059	941	774	983	1,008	909	902	1,036	1,066
NOPAT Margin	17.46%	25.03%	28.47%	26.53%	24.62%	28.63%	29.98%	28.78%	28.54%	30.35%	36.32%
Net Nonoperating Expense Percent (NNEP)	1.88%	-0.21%	1.97%	3.59%	-0.39%	1.40%	0.00%	0.50%	-0.71%	1.45%	2.53%
Return On Investment Capital (ROIC_SIMPLE)	1.65%	2.96%	-	-	-	3.43%	-	-	-	4.09%	-
Cost of Revenue to Revenue	15.33%	14.92%	13.20%	13.54%	13.79%	15.05%	12.98%	12.82%	14.47%	15.83%	10.82%
SG&A Expenses to Revenue	20.90%	20.91%	19.20%	21.39%	21.91%	21.48%	19.05%	20.65%	19.01%	19.34%	18.02%
R&D to Revenue	44.23%	37.63%	35.68%	34.50%	39.92%	35.15%	34.95%	34.37%	36.60%	31.43%	31.04%
Operating Expenses to Revenue	65.13%	58.95%	55.10%	56.31%	62.31%	56.62%	53.98%	54.99%	55.59%	50.58%	47.50%
Earnings before Interest and Taxes (EBIT)	914	969	1,507	1,643	717	1,166	1,129	1,102	876	1,342	1,525
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,041	1,095	1,629	1,764	831	1,279	1,234	1,205	976	1,442	1,618
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.36	2.67	3.95	4.11	3.89	3.68	3.59	3.28	3.82	3.47	3.50
Price to Tangible Book Value (P/TBV)	2.46	2.78	4.11	4.27	4.04	3.84	3.74	3.42	3.98	3.61	3.64
Price to Revenue (P/Rev)	4.92	5.51	8.37	8.59	8.00	7.29	6.82	6.22	7.26	6.45	5.48
Price to Earnings (P/E)	15.41	17.74	24.90	26.80	27.18	24.20	22.38	18.34	21.48	18.11	13.98
Dividend Yield	0.14%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	6.49%	5.64%	4.02%	3.73%	3.68%	4.13%	4.47%	5.45%	4.66%	5.52%	7.15%
Enterprise Value to Invested Capital (EV/IC)	3.76	4.46	7.30	7.55	7.38	6.61	6.41	5.78	6.94	6.07	5.81
Enterprise Value to Revenue (EV/Rev)	3.86	4.44	7.24	7.49	6.88	6.26	5.83	5.23	6.27	5.50	4.73
Enterprise Value to EBITDA (EV/EBITDA)	9.84	11.86	18.23	19.77	19.80	17.50	15.72	12.65	15.24	12.73	10.11
Enterprise Value to EBIT (EV/EBIT)	10.81	13.04	19.93	21.70	21.90	19.23	17.16	13.68	16.42	13.61	10.63
Enterprise Value to NOPAT (EV/NOPAT)	15.74	17.12	26.95	27.45	24.50	21.56	19.83	16.99	19.49	15.82	11.69
Enterprise Value to Operating Cash Flow (EV/OCF)	13.77	14.27	23.61	24.81	19.01	17.88	14.61	13.99	18.11	13.35	11.43
Enterprise Value to Free Cash Flow (EV/FCFF)	45.82	31.96	52.96	57.18	33.98	34.13	24.76	35.97	60.22	47.27	29.29
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.09	0.09	0.09	0.10	0.10	0.10	0.11	0.11	0.12	0.12	0.13
Long-Term Debt to Equity	0.09	0.09	0.09	0.10	0.10	0.10	0.11	0.11	0.12	0.12	0.13
Financial Leverage	-0.53	-0.52	-0.53	-0.52	-0.54	-0.52	-0.50	-0.53	-0.55	-0.54	-0.51
Leverage Ratio	1.28	1.28	1.28	1.28	1.28	1.28	1.29	1.29	1.30	1.32	1.33
Compound Leverage Factor	1.26	1.27	1.27	1.27	1.25	1.26	1.27	1.27	1.27	1.30	1.31
Debt to Total Capital	8.43%	8.44%	8.44%	8.75%	9.10%	9.43%	9.79%	10.11%	10.31%	10.65%	11.19%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	8.43%	8.44%	8.44%	8.75%	9.10%	9.43%	9.79%	10.11%	10.31%	10.65%	11.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.57%	91.56%	91.56%	91.25%	90.90%	90.57%	90.21%	89.89%	89.69%	89.35%	88.81%
Debt to EBITDA	0.49	0.51	0.49	0.53	0.59	0.58	0.56	0.52	0.53	0.51	0.42
Net Debt to EBITDA	-2.70	-2.86	-2.83	-2.90	-3.25	-2.88	-2.67	-2.40	-2.42	-2.21	-1.61
Long-Term Debt to EBITDA	0.49	0.51	0.49	0.53	0.59	0.58	0.56	0.52	0.53	0.51	0.42
Debt to NOPAT	0.78	0.73	0.73	0.73	0.74	0.71	0.70	0.69	0.68	0.64	0.49
Net Debt to NOPAT	-4.31	-4.13	-4.19	-4.03	-4.02	-3.55	-3.37	-3.22	-3.10	-2.75	-1.86
Long-Term Debt to NOPAT	0.78	0.73	0.73	0.73	0.74	0.71	0.70	0.69	0.68	0.64	0.49
Altman Z-Score	7.21	7.69	10.72	11.00	10.65	10.33	9.60	9.34	10.39	9.41	9.56
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.93	4.73	5.28	5.44	5.27	5.69	5.18	5.45	5.45	5.06	5.36
Quick Ratio	3.90	3.86	4.34	4.43	4.40	4.82	4.31	4.53	4.54	4.16	4.37
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,742	-762	-768	-972	-251	-420	243	-1,150	-1,788	-1,779	-2,265
Operating Cash Flow to CapEx	455.78%	632.67%	533.77%	196.12%	1,129.57%	433.45%	633.13%	904.78%	767.45%	1,130.03%	441.33%
Free Cash Flow to Firm to Interest Expense	-200.21	-72.60	-55.69	-65.66	-15.60	-22.97	13.63	-60.85	-99.33	-102.23	-148.01
Operating Cash Flow to Interest Expense	120.13	120.27	93.57	23.92	93.94	59.55	62.60	54.10	75.98	98.84	41.10
Operating Cash Flow Less CapEx to Interest Expense	93.77	101.26	76.04	11.72	85.63	45.81	52.71	48.12	66.08	90.10	31.79
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.39	0.40	0.40	0.40	0.41	0.42	0.44	0.44	0.44	0.45	0.53
Accounts Receivable Turnover	2.61	2.39	2.37	2.49	2.53	2.39	2.35	2.46	2.48	2.14	2.49
Inventory Turnover	0.68	0.70	0.69	0.69	0.70	0.73	0.74	0.73	0.73	0.72	0.90
Fixed Asset Turnover	3.16	3.25	3.28	3.28	3.23	3.32	3.40	3.35	3.33	3.36	3.86
Accounts Payable Turnover	2.91	2.82	3.72	3.37	2.82	3.04	3.43	3.18	3.02	2.71	4.16
Days Sales Outstanding (DSO)	139.71	152.65	154.09	146.64	144.06	152.99	155.13	148.10	146.91	170.39	146.43
Days Inventory Outstanding (DIO)	538.77	524.93	529.81	525.91	523.40	500.76	493.53	501.24	499.66	509.14	407.03
Days Payable Outstanding (DPO)	125.57	129.30	98.17	108.38	129.41	120.19	106.38	114.70	121.04	134.88	87.73
Cash Conversion Cycle (CCC)	552.91	548.28	585.74	564.17	538.04	533.57	542.27	534.64	525.53	544.65	465.73
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	14,467	14,145	13,743	13,378	12,196	12,435	11,915	11,465	11,171	11,031	11,150
Invested Capital Turnover	1.06	1.07	1.08	1.09	1.12	1.12	1.14	1.21	1.26	1.26	1.45
Increase / (Decrease) in Invested Capital	2,271	1,711	1,828	1,913	1,025	1,403	765	2,059	2,690	2,815	3,331
Enterprise Value (EV)	54,416	63,069	100,300	100,980	90,065	82,149	76,350	66,279	77,505	66,939	64,803
Market Capitalization	69,337	78,278	115,883	115,808	104,860	95,687	89,339	78,831	89,830	78,572	75,093
Book Value per Share	$268.81	$267.12	$266.03	$255.98	$250.38	$238.40	$229.41	$218.92	$214.91	$208.11	$196.67
Tangible Book Value per Share	$258.14	$256.67	$255.87	$245.98	$240.56	$228.87	$220.04	$210.23	$206.42	$199.71	$189.29
Total Capital	32,092	32,058	32,030	30,910	29,695	28,676	27,607	26,720	26,197	25,366	24,140
Total Debt	2,705	2,704	2,704	2,704	2,703	2,703	2,703	2,702	2,702	2,701	2,701
Total Long-Term Debt	2,705	2,704	2,704	2,704	2,703	2,703	2,703	2,702	2,702	2,701	2,701
Net Debt	-14,921	-15,208	-15,583	-14,828	-14,795	-13,538	-12,990	-12,553	-12,325	-11,633	-10,289
Capital Expenditures (CapEx)	229	200	242	181	134	251	176	113	178	152	143
Debt-free, Cash-free Net Working Capital (DFCFNWC)	5,656	5,704	5,876	5,764	4,771	5,211	5,123	4,891	4,849	5,001	5,528
Debt-free Net Working Capital (DFNWC)	14,005	14,717	15,673	15,573	15,291	16,056	15,036	13,819	13,809	12,743	12,549
Net Working Capital (NWC)	14,005	14,717	15,673	15,573	15,291	16,056	15,036	13,819	13,809	12,743	12,549
Net Nonoperating Expense (NNE)	-280	31	-281	-491	52	-177	0.18	-59	85	-161	-249
Net Nonoperating Obligations (NNO)	-14,921	-15,208	-15,584	-14,828	-14,795	-13,538	-12,990	-12,553	-12,325	-11,633	-10,289
Total Depreciation and Amortization (D&A)	127	126	122	121	114	113	105	103	100	100	93
Debt-free, Cash-free Net Working Capital to Revenue	40.15%	40.16%	42.44%	42.73%	36.42%	39.73%	39.11%	38.60%	39.20%	41.08%	40.32%
Debt-free Net Working Capital to Revenue	99.43%	103.62%	113.18%	115.45%	116.72%	122.40%	114.80%	109.06%	111.63%	104.68%	91.53%
Net Working Capital to Revenue	99.43%	103.62%	113.18%	115.45%	116.72%	122.40%	114.80%	109.06%	111.63%	104.68%	91.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$7.58	$8.55	$12.40	$13.25	$6.70	$10.88	$9.48	$9.05	$7.64	$11.18	$12.31
Adjusted Weighted Average Basic Shares Outstanding	106.70M	107.90M	108.10M	108.10M	107.80M	106.70M	106.30M	107M	107.10M	107.10M	106.90M
Adjusted Diluted Earnings per Share	$7.27	$8.12	$11.54	$12.41	$6.27	$10.21	$8.89	$8.50	$7.17	$10.48	$11.66
Adjusted Weighted Average Diluted Shares Outstanding	111.20M	115.10M	116.20M	115.40M	115.10M	113.70M	113.40M	113.90M	114M	113.50M	112.80M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	107.97M	109.32M	109.89M	110.23M	110.19M	109.76M	108.95M	108.56M	109.71M	109.33M	108.90M
Normalized Net Operating Profit after Tax (NOPAT)	529	948	1,059	941	526	681	1,008	909	902	1,036	1,066
Normalized NOPAT Margin	17.46%	25.03%	28.47%	26.53%	16.72%	19.83%	29.98%	28.78%	28.54%	30.35%	36.32%
Pre Tax Income Margin	29.88%	25.29%	40.13%	45.90%	22.28%	33.42%	33.03%	34.29%	27.13%	38.80%	51.42%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	105.02	92.25	109.19	111.01	44.52	63.71	63.40	58.30	48.67	77.13	99.68
NOPAT to Interest Expense	60.77	90.33	76.75	63.58	48.09	53.72	56.63	48.10	50.13	59.56	69.70
EBIT Less CapEx to Interest Expense	78.67	73.24	91.66	98.81	36.21	49.97	53.52	52.32	38.77	68.39	90.37
NOPAT Less CapEx to Interest Expense	34.42	71.32	59.22	51.38	39.77	39.98	46.74	42.12	40.23	50.81	60.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	74.53%	59.00%	41.24%	40.05%	47.06%	56.53%	59.56%	64.32%	58.23%	48.01%	46.90%

Frequently Asked Questions About Regeneron Pharmaceuticals' Financials

When does Regeneron Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Regeneron Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Regeneron Pharmaceuticals' net income changed over the last 9 years?

Regeneron Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $4.41 billion in 2024, rising from $636.06 million in 2015. The previous period was $3.95 billion in 2023. Find out what analysts predict for Regeneron Pharmaceuticals in the coming months.

What is Regeneron Pharmaceuticals's operating income?

Regeneron Pharmaceuticals's total operating income in 2024 was $3.99 billion, based on the following breakdown:

Total Gross Profit: $12.23 billion
Total Operating Expenses: $8.24 billion

How has Regeneron Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Regeneron Pharmaceuticals' total revenue changed from $4.10 billion in 2015 to $14.20 billion in 2024, a change of 246.1%.

How much debt does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals' total liabilities were at $8.41 billion at the end of 2024, a 18.3% increase from 2023, and a 330.1% increase since 2015.

How much cash does Regeneron Pharmaceuticals have?

In the past 9 years, Regeneron Pharmaceuticals' cash and equivalents has ranged from $535.20 million in 2016 to $3.11 billion in 2022, and is currently $2.49 billion as of their latest financial filing in 2024.

How has Regeneron Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Regeneron Pharmaceuticals' book value per share changed from 35.12 in 2015 to 267.12 in 2024, a change of 660.6%.

Related Companies

This page (NASDAQ:REGN) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Financials

Frequently Asked Questions About Regeneron Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Financials

Annual Income Statements for Regeneron Pharmaceuticals

Quarterly Income Statements for Regeneron Pharmaceuticals

Annual Cash Flow Statements for Regeneron Pharmaceuticals

Quarterly Cash Flow Statements for Regeneron Pharmaceuticals

Annual Balance Sheets for Regeneron Pharmaceuticals

Quarterly Balance Sheets for Regeneron Pharmaceuticals

Annual Metrics And Ratios for Regeneron Pharmaceuticals

Quarterly Metrics And Ratios for Regeneron Pharmaceuticals

Frequently Asked Questions About Regeneron Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools